Rallybio Corp. (RLYB)
16.94
+0.25
(+1.50%)
USD |
NASDAQ |
Sep 02, 16:00
17.05
+0.11
(+0.65%)
Pre-Market: 20:00
Rallybio Research and Development Expense (Annual) : 16.30M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 16.30M |
| December 31, 2024 | 41.38M |
| December 31, 2023 | 53.39M |
| December 31, 2022 | 40.52M |
| Date | Value |
|---|---|
| December 31, 2021 | 26.80M |
| December 31, 2020 | 17.57M |
| December 31, 2019 | 11.34M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Q32 Bio, Inc. | 19.16M |
| Beam Therapeutics, Inc. | 409.62M |
| C4 Therapeutics, Inc. | 104.24M |
| Cullinan Therapeutics, Inc. | 187.40M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |